We are live on ! Find out more
RNAZ icon

TransCode Therapeutics
RNAZ

1 hedge funds and large institutions have $2.27M invested in TransCode Therapeutics in 2022 Q3 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 1 → 1 (0)

0% more ownership

Funds ownership: 0% → 0% (0%)

15% less capital invested

Capital invested by funds: $2.67M → $2.27M (-$394K)

Holders
1
Holders Change
–
Holders Change %
0%
% of All Funds
0.02%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
-$25K
Name Holding Trade Value Shares
Change 		Change in
Stake
ACM
1
AIGH Capital Management
Maryland
$1.42M – – –
WVP
2
Worth Venture Partners
New Jersey
$357K – – –
Vanguard Group
3
Vanguard Group
Pennsylvania
$220K – – –
RAM
4
Redmond Asset Management
Virginia
$100K – – –
Geode Capital Management
5
Geode Capital Management
Massachusetts
$84K – – –
State Street
6
State Street
Massachusetts
$23K – – –
KJHP
7
K.J. Harrison & Partners
Ontario, Canada
$22K – – –
BlackRock
8
BlackRock
New York
$17K – – –
SC
9
Shay Capital
New York
$17K – – –
ACM
10
ACT Capital Management
Pennsylvania
$7K – – –
TRCT
11
Tower Research Capital (TRC)
New York
$6K – – –
Renaissance Technologies
12
Renaissance Technologies
New York
– -$25K – –

RNAZ Hedge Fund Activity: Q3 2022 in Review

1 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in TransCode Therapeutics (RNAZ) for Q3 2022, worth a combined $2.27M — down 15% from $2.67M a quarter earlier.

Fund positioning in RNAZ was balanced in Q3 2022: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 0 trimmed.

The largest seller was Renaissance Technologies, cutting an estimated $25K.

  • 1 institutional investor held TransCode Therapeutics (RNAZ) as of Q3 2022, unchanged from Q2 2022.
  • Funds reported $2.27M of TransCode Therapeutics stock for Q3 2022, down 15% quarter-over-quarter.
  • 0 funds opened new TransCode Therapeutics positions in Q3 2022 and 0 closed out.
  • The largest TransCode Therapeutics seller in Q3 2022 was Renaissance Technologies, an estimated $25K sold.

Based on aggregated 13F filings for Q3 2022.